{"title":"Generative artificial intelligence, integrative bioinformatics, and single-cell analysis reveal Alzheimer's genetic and immune landscape.","authors":"Arpita Das, Manojit Bhattacharya, Ali Saber Abdelhameed, Sang-Soo Lee, Chiranjib Chakraborty","doi":"10.1016/j.omtn.2025.102546","DOIUrl":null,"url":null,"abstract":"<p><p>The research aims to understand Alzheimer's genetic and immune landscapes using the amalgamation of three technologies: artificial intelligence (GenAI), integrative bioinformatics, and single-cell analysis. First, the study aims to identify and characterize the significant genes associated with Alzheimer's disease (AD) using three GenAI models (GPT‑4o, Gemini model, and DeepSeek). After the genes were accumulated from GenAI models, 27 genes associated with AD were recoded. Furthermore, they were analyzed using integrative bioinformatics methods. Similarly, the immune landscape of AD using single-cell analysis was also explored, which reveals a high percentage of effector CD8<sup>+</sup> T cells (33.42%) and naive T cells (45.95%). The single-cell study found that effector memory T cells have two subsets. It also found that the macrophage population has started to spread and dendritic cells have decreased in Alzheimer's patients. The single-cell gene expression study reveals the top ten highly expressed genes (<i>NDUFV2</i>, <i>CAT</i>, <i>MRPS34</i>, <i>PBX3</i>, <i>THOC2</i>, <i>CCDC57</i>, <i>PBXIP1</i>, <i>SDHAF3</i>, <i>PPP4C</i>, and <i>MAP3K8</i>). The clonal frequency indicates that CD8<sup>+</sup> T and naive T cell populations show the highest clonal frequency in healthy and AD individuals and are further noted them in the clonotype cell proportion study. Following our GenAI and single-cell profiling strategy, future studies will help in quickly understanding the genetic and immune basis of many diseases.</p>","PeriodicalId":18821,"journal":{"name":"Molecular Therapy. Nucleic Acids","volume":"36 2","pages":"102546"},"PeriodicalIF":6.1000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148819/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy. Nucleic Acids","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omtn.2025.102546","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/10 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
The research aims to understand Alzheimer's genetic and immune landscapes using the amalgamation of three technologies: artificial intelligence (GenAI), integrative bioinformatics, and single-cell analysis. First, the study aims to identify and characterize the significant genes associated with Alzheimer's disease (AD) using three GenAI models (GPT‑4o, Gemini model, and DeepSeek). After the genes were accumulated from GenAI models, 27 genes associated with AD were recoded. Furthermore, they were analyzed using integrative bioinformatics methods. Similarly, the immune landscape of AD using single-cell analysis was also explored, which reveals a high percentage of effector CD8+ T cells (33.42%) and naive T cells (45.95%). The single-cell study found that effector memory T cells have two subsets. It also found that the macrophage population has started to spread and dendritic cells have decreased in Alzheimer's patients. The single-cell gene expression study reveals the top ten highly expressed genes (NDUFV2, CAT, MRPS34, PBX3, THOC2, CCDC57, PBXIP1, SDHAF3, PPP4C, and MAP3K8). The clonal frequency indicates that CD8+ T and naive T cell populations show the highest clonal frequency in healthy and AD individuals and are further noted them in the clonotype cell proportion study. Following our GenAI and single-cell profiling strategy, future studies will help in quickly understanding the genetic and immune basis of many diseases.
期刊介绍:
Molecular Therapy Nucleic Acids is an international, open-access journal that publishes high-quality research in nucleic-acid-based therapeutics to treat and correct genetic and acquired diseases. It is the official journal of the American Society of Gene & Cell Therapy and is built upon the success of Molecular Therapy. The journal focuses on gene- and oligonucleotide-based therapies and publishes peer-reviewed research, reviews, and commentaries. Its impact factor for 2022 is 8.8. The subject areas covered include the development of therapeutics based on nucleic acids and their derivatives, vector development for RNA-based therapeutics delivery, utilization of gene-modifying agents like Zn finger nucleases and triplex-forming oligonucleotides, pre-clinical target validation, safety and efficacy studies, and clinical trials.